This review highlights the fundamental components and current challenges in developing effective gene therapies for dystrophin-deficient cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Does not yet support clinical AAV gene therapy; leaves open optimal gene, expression, and target selection for dystrophin cardiomyopathy.
Dongsheng Duan (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: